Antibiotic resistance test for gonorrhea gets FDA breakthrough nod

  15 June 2019

FDA granted a breakthrough designation to Australia-based SpeeDx to expedite the path to U.S. clearance for a molecular test that detects both N. gonorrhea and a patient’s susceptibility or resistance to the antibiotic ciprofloxacin.

Results from the ResistancePlus GC test can be used to determine whether patients can be treated with ciprofloxacin rather than ceftriaxone, the current front-line treatment for gonorrhea.

There have been reports in the United Kingdom and Australia of resistance to ceftriaxone, an antibiotic used to treat many kinds of bacterial infections, including organisms that are resistant to other antibiotics.

Further reading: MedTechDive
Healthy Patients   Smart Innovations  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

LifeArc

Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS





AMR NEWS

Every two weeks in your inbox

Because there should be one newsletter that brings together all One Health news related to antimicrobial resistance: AMR NEWS!

Subscribe

What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!

Keep me informed